No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
FDA Accepts Roche’s sBLA For Susvimo® (Ranibizumab) for DME and DR
On 18 July 2024, Roche announced that FDA has accepted its supplemental BLA for Susvimo®, a refillable ocular implant containing a specialised formulation of ranibizumab, for the treatment of diabetic macular oedema (DME) and diabetic retinopathy (DR). This follows...